These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 33973580)

  • 1. Doxorubicin and PD-L1 siRNA co-delivery with stem cell membrane-coated polydopamine nanoparticles for the targeted chemoimmunotherapy of PCa bone metastases.
    Mu X; Zhang M; Wei A; Yin F; Wang Y; Hu K; Jiang J
    Nanoscale; 2021 May; 13(19):8998-9008. PubMed ID: 33973580
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combinational Chemoimmunotherapy for Breast Cancer by Codelivery of Doxorubicin and PD-L1 siRNA Using a PAMAM-Incorporated Liposomal Nanoplatform.
    Hu Q; Yao J; Wang X; Wang Y; Fu X; Ma J; Lin H; Xu J; Shen L; Yu X
    ACS Appl Mater Interfaces; 2022 Feb; 14(7):8782-8792. PubMed ID: 35138103
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Doxorubicin and siRNA-PD-L1 co-delivery with T7 modified ROS-sensitive nanoparticles for tumor chemoimmunotherapy.
    Wan WJ; Qu CX; Zhou YJ; Zhang L; Chen MT; Liu Y; You BG; Li F; Wang DD; Zhang XN
    Int J Pharm; 2019 Jul; 566():731-744. PubMed ID: 31212055
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polydopamine-Based Nanoparticles for Synergistic Chemotherapy of Prostate Cancer.
    Hu K; Zhang D; Ma W; Gu Y; Zhao J; Mu X
    Int J Nanomedicine; 2024; 19():6717-6730. PubMed ID: 38979530
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functionalized biomimetic nanoparticles combining programmed death-1/programmed death-ligand 1 blockade with photothermal ablation for enhanced colorectal cancer immunotherapy.
    Xiao Y; Zhu T; Zeng Q; Tan Q; Jiang G; Huang X
    Acta Biomater; 2023 Feb; 157():451-466. PubMed ID: 36442821
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polydopamine Nanoparticles Camouflaged by Stem Cell Membranes for Synergistic Chemo-Photothermal Therapy of Malignant Bone Tumors.
    Zhang M; Zhang F; Liu T; Shao P; Duan L; Yan J; Mu X; Jiang J
    Int J Nanomedicine; 2020; 15():10183-10197. PubMed ID: 33363374
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stimuli-responsive nanoparticles for the codelivery of chemotherapeutic agents doxorubicin and siPD-L1 to enhance the antitumor effect.
    Zhou YJ; Wan WJ; Tong Y; Chen MT; Wang DD; Wang Y; You BG; Liu Y; Zhang XN
    J Biomed Mater Res B Appl Biomater; 2020 May; 108(4):1710-1724. PubMed ID: 31746127
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Coadministration of iRGD peptide with ROS-sensitive nanoparticles co-delivering siFGL1 and siPD-L1 enhanced tumor immunotherapy.
    Wan WJ; Huang G; Wang Y; Tang Y; Li H; Jia CH; Liu Y; You BG; Zhang XN
    Acta Biomater; 2021 Dec; 136():473-484. PubMed ID: 34571271
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-PD-L1 peptide-conjugated prodrug nanoparticles for targeted cancer immunotherapy combining PD-L1 blockade with immunogenic cell death.
    Moon Y; Shim MK; Choi J; Yang S; Kim J; Yun WS; Cho H; Park JY; Kim Y; Seong JK; Kim K
    Theranostics; 2022; 12(5):1999-2014. PubMed ID: 35265195
    [No Abstract]   [Full Text] [Related]  

  • 10. Regulating the immunosuppressive tumor microenvironment to enhance breast cancer immunotherapy using pH-responsive hybrid membrane-coated nanoparticles.
    Gong C; Yu X; Zhang W; Han L; Wang R; Wang Y; Gao S; Yuan Y
    J Nanobiotechnology; 2021 Feb; 19(1):58. PubMed ID: 33632231
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dissolving microneedles-based programmed delivery system for enhanced chemo-immunotherapy of melanoma.
    Tian Y; Jing H; Wang Q; Hu S; Wu Z; Duan Y
    J Control Release; 2023 Aug; 360():630-646. PubMed ID: 37414221
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A tumor extracellular pH-sensitive PD-L1 binding peptide nanoparticle for chemo-immunotherapy of cancer.
    Zhu W; Bai Y; Zhang N; Yan J; Chen J; He Z; Sun Q; Pu Y; He B; Ye X
    J Mater Chem B; 2021 May; 9(20):4201-4210. PubMed ID: 33997867
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted Nanobubbles of PD-L1 mAb Combined with Doxorubicin as a Synergistic Tumor Repressor in Hepatocarcinoma.
    Chen Y; Luo X; Liu Y; Zou Y; Yang S; Liu C; Zhao Y
    Int J Nanomedicine; 2022; 17():3989-4008. PubMed ID: 36105615
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GE11-modified carboxymethyl chitosan micelles to deliver DOX·PD-L1 siRNA complex for combination of ICD and immune escape inhibition against tumor.
    Song P; Wang B; Pan Q; Jiang T; Chen X; Zhang M; Tao J; Zhao X
    Carbohydr Polym; 2023 Jul; 312():120837. PubMed ID: 37059562
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chitosan coated pH/redox-responsive hyaluronic acid micelles for enhanced tumor targeted co-delivery of doxorubicin and siPD-L1.
    Song P; Lu Z; Jiang T; Han W; Chen X; Zhao X
    Int J Biol Macromol; 2022 Dec; 222(Pt A):1078-1091. PubMed ID: 36183754
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reprogramming the T cell response to cancer by simultaneous, nanoparticle-mediated PD-L1 inhibition and immunogenic cell death.
    Phung CD; Nguyen HT; Choi JY; Pham TT; Acharya S; Timilshina M; Chang JH; Kim JH; Jeong JH; Ku SK; Choi HG; Yong CS; Kim JO
    J Control Release; 2019 Dec; 315():126-138. PubMed ID: 31672625
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Doxorubicin and Anti-PD-L1 Antibody Conjugated Gold Nanoparticles for Colorectal Cancer Photochemotherapy.
    Emami F; Banstola A; Vatanara A; Lee S; Kim JO; Jeong JH; Yook S
    Mol Pharm; 2019 Mar; 16(3):1184-1199. PubMed ID: 30698975
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Synergistic Chemoimmunotherapy System Leveraging PD-L1 Blocking and Bioorthogonal Prodrug Activation.
    Wang K; Jiang M; Li T; Liu Y; Zong Q; Xu Q; Ullah I; Chen Y; Xue W; Yuan Y
    Adv Mater; 2024 Jul; 36(30):e2402322. PubMed ID: 38718226
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune checkpoint silencing using RNAi-incorporated nanoparticles enhances antitumor immunity and therapeutic efficacy compared with antibody-based approaches.
    Won JE; Byeon Y; Wi TI; Lee CM; Lee JH; Kang TH; Lee JW; Lee Y; Park YM; Han HD
    J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35228265
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Construction of aptamer-siRNA chimera and glutamine modified carboxymethyl-β-cyclodextrin nanoparticles for the combination therapy against lung squamous cell carcinoma.
    Hao Y; Yang J; Liu D; Zhang H; Ou T; Xiao L; Chen W
    Biomed Pharmacother; 2024 May; 174():116506. PubMed ID: 38554525
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.